Send to

Choose Destination
Int J Cardiol. 2018 Jun 2. pii: S0167-5273(18)30187-6. doi: 10.1016/j.ijcard.2018.06.001. [Epub ahead of print]

Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure.

Author information

St. Martha's Regional Hospital, Antigonish, Nova Scotia, Canada. Electronic address:
Cardiology Department, The Adelaide and Meath Hospital, Tallaght, Dublin, Ireland.
Department of Physiology and Biophysics, Dalhousie University, Halifax, NS, Canada.


Pulmonary hypertension (PH) due to left ventricular heart failure (LV-HF) is a disabling and life-threatening disease for which there is currently no single marketed pharmacological agent approved. Despite recent advances in the pathophysiological understanding, there is as yet no prospect of cure, and the majority of patients continue to progress to right ventricular failure and die. There is, therefore an urgent unmet need to identify novel pharmacological agents that will prevent or reverse the increase in pulmonary artery pressures while enhancing cardiac performance in PH due to LV-HF. In the present article, we first focused on the Natriuretic Peptide Receptor type C (NPR-C) based therapeutic strategies aimed at lowering pulmonary artery pressure. Second, we reviewed potential NPR-C therapeutic strategies to reverse or least halt the detrimental effects of diastolic dysfunction and impaired nitic oxide signalling pathways, as well as possibilities for neurohumoral modulation.


LV-HF, left ventricular heart failure; NPR-C, natriuretic peptides clearance receptor (type C); PH, pulmonary hypertension

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center